Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSS | P25774 | 7/20 | 0.59 |
| ▸ | CTSK | P43235 | 6/20 | 0.59 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | AAK1 | Q2M2I8 | 3/20 | 0.46 |
| ▸ | CTSB | P07858 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.43 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL740136 | 1.00 | CTSS (0.59) | CTSSCTSKATMCACNA1BAPP | |
| SCHEMBL2617247 | 1.00 | CTSS (0.59) | CTSSCTSKATMCACNA1BAPP | |
| SCHEMBL16942400 | 0.90 | CTSS (0.56) | CTSSCTSKATMCACNA1BAPP | |
| SCHEMBL29163523 | 0.88 | ATM (0.56) | CTSSCTSKATMAPPCTSB | |
| SCHEMBL1519889 | 0.88 | ATM (0.56) | CTSSCTSKATMAPPCTSB | |
| SCHEMBL28132845 | 0.88 | ATM (0.60) | CTSSCTSKATMAPPCTSB | |
| SCHEMBL7897952 | 0.88 | ATM (0.56) | CTSSCTSKATMAPPCTSB | |
| SCHEMBL489489 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPCTSB | |
| SCHEMBL1519945 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPCTSB | |
| SCHEMBL489490 | 0.88 | ATM (0.70) | CTSSCTSKATMAPPCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119591542-A | ADAR1 small molecule inhibitor, pharmaceutical composition and application thereof | 深圳市新樾生物科技有限公司 | 2025-03-11 | — | — | CN | disclosed |
| CN-117486762-A | Novel compound and use method and application thereof | 中国医学科学院医药生物技术研究所 | 2024-02-02 | — | — | CN | disclosed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | disclosed |
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | NOVARTIS AG (CH) | 2018-10-30 | — | — | US | disclosed |
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2018-07-12 | — | — | US | disclosed |
| EP-2956464-B1 | SUBSTITUTED BISPHENYL BUTANOIC PHOSPHONIC ACID DERIVATIVES AS NEP (NEUTRAL ENDOPEPTIDASE) INHIBITORS | NOVARTIS AG (CH) | 2018-03-28 | — | — | EP | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-9839639-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2017-07-06 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | NOVARTIS AG (CH) | 2012-05-17 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8138168-B1 | Renin inhibitors | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | NOVARTIS AG (CH) | 2010-12-02 | — | — | US | disclosed |
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111634-A2 | RENIN INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10112963-B2 | Substituted bisphenyl butanoic phosphonic acid derivatives as NEP inhibitors | MME, REN, ENPP1 | CTSS 1824/4885CTSK 2924/4885ATM 4819/4885 |
| US-20180193338-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CTSS 98/4885CTSK 182/4885ATM 4866/4885 |
| US-20100305131-A1 | Substituted Aminopropionic Derivatives as Neprilysin inhibitors | MME, AGTR1, REN | CTSS 730/4885CTSK 1421/4885ATM 4747/4885 |
| US-20120122844-A1 | METHOD OF TREATING CONTRAST-INDUCED NEPHROPATHY | REN, SERPINB1, MME | CTSS 88/4885CTSK 179/4885ATM 4052/4885 |
| US-20170189399-A1 | NEPRILYSIN INHIBITORS | MME, REN, ACE | CTSS 98/4885CTSK 182/4885ATM 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.